Orientador: José Luiz Moraes Vasconcelos / Resumo: O objetivo deste estudo foi avaliar se vacas Nelore, que receberam duas doses de PGF2α em protocolos de IATF a base de progesterona e estradiol, teriam melhor fertilidade em comparação a uma dose de PGF2α. Foram realizados 2 experimentos em que os animais receberam o protocolo de IATF: dispositivo intravaginal de P4 (CIDR) e 2,0 mg benzoato de estradiol (i.m., 2 ml Gonadiol®, Zoetis), no d-11, dinoprost trometamina (PGF2α; i.m., 2,5 ml Lutalyse®, Zoetis) no d-4, retirada do dispositivo de P4, 0,6 mg de cipionato de estradiol (i.m., 0,3 ml ECP®, Zoetis) e 300 UI de eCG (i.m., 1,5 ml Novormon®, Zoetis) no d-2, e IATF no d0. No experimento 1, as vacas (n=1.039) foram divididas aleatoriamente para receber uma ou duas doses de PGF2α, sendo a primeira no d-4 e a segunda no d-2. No experimento 2, foram avaliadas 1.051 fêmeas Nelore, permanecendo para as análises deste estudo apenas fêmeas que não apresentaram um CL no d-4 (momento da primeira PGF2α; n=934), os tratamentos foram os mesmos descritos no experimento 1. Foi fixado um dispositivo para avaliar a expressão do cio (Estrotect®) no d-2, avaliado o diâmetro folicular no d0, as colheitas de sangue foram realizadas no d0 e d7, para dosagem de P4. O diagnóstico de gestação (DG) foi realizado 30 dias após IA. No experimento 1, a taxa de prenhez foi maior para os animais do grupo 2PG (54,5% vs. 46,6%; P = 0,01) em relação a 1PG. No experimento 2, a taxa de sincronização e a taxa de prenhez foram maiores no grupo 2PG, (81,4% vs. 72,1... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: The aim of this study was to evaluate whether Nelore cows that received two doses of PGF2α in progesterone and estradiol-based TAI protocols would have better fertility compared to one dose of PGF2α. Two experiments were performed in which the animals received an TAI protocol: intravaginal P4 device (CIDR) and 2.0 mg estradiol benzoate (i.m., 2 ml Gonadiol®, Zoetis) at d-11, dinoprost tromethamine (PGF2α; i.m., 2 , 5 ml Lutalyse®, Zoetis) at d-4, P4 device withdrawal, 0.6 mg estradiol cypionate (i.m., 0.3 ml ECP®, Zoetis) and 300 IU eCG (i.m., 1.5 ml Novormon®, Zoetis) at d-2, and AI at d0. In experiment 1 the animals (n = 1,039) were randomly assigned to receive one or two doses of PGF2α, the first on d-4 and the second on d-2. In experiment 2, 1,051 Nelore cows were used, and remaining for the analysis of this study only females without CL on d-4 (moment of first PGF2α; n=934), the treatments were the same as described in experiment 1. A device was fixed to evaluate estrus expression (Estrotect®) at d-2, measured follicular diameter at d0, blood samples were collected at d0 and d7 for P4 dosage. The pregnancy diagnosis was made 30 days after AI. In experiment 1, the pregnancy rate was higher for animals in group 2PG (54.5% vs. 46.6%; P = 0.01) compared to 1PG. In experiment 2, synchronization rate and pregnancy rate were higher in group 2PG (81.4% vs. 72.1%; [P = 0.01] and 55.5% vs. 45.6%; [P = 0.04], respectively) only in animals with BCS < 5.0 (scale from 1 to 9). In anim... (Complete abstract click electronic access below) / Mestre

Orientador: Claudia Maria Bertan Membrive / Banca: Flávia Simone Munin / Banca: Fábio Ermínio Mingatto / Resumo: Em fêmeas bovinas, a liberação de prostaglandina F2a (PGF2a) pode ser induzida in vivo pelo estradiol (E2), entretanto, o papel do E2 na síntese de PGF2a ainda não foi esclarecido. Considerando que as concentrações plasmáticas de PGF2a aumentam 3,5 horas após a aplicação de E2 in vivo, acredita-se que o E2 ative não somente enzimas, mas também estimule a síntese de proteínas essenciais para a produção de PGF2a, como a PKC e PLA2. O presente estudo objetivou avaliar o efeito do E2 no incremento da concentração das proteínas totais no endométrio e na modificação da composição protéica de explantes endometriais de fêmeas bovinas tratadas com E2 no 17º dia do ciclo estral. A hipótese é que a administração de E2 em fêmeas bovinas no 17º dia do ciclo estral incrementa a concentração de proteínas no endométrio e modifica a composição protéica nos explantes endometriais. Para tanto, fêmeas bovinas mestiças (Bos taurus taurus vs Bos taurus indicus) foram tratadas no 17° dia do ciclo estral, via intravenosa, com 0mg (Grupo Controle; n=6) ou 3mg de E2 (Grupo E2; n=6) e abatidas duas horas após o tratamento. Explantes endometriais foram isolados e submetidos à extração de proteínas totais. As amostras de proteínas, referentes aos explantes de cada animal, foram avaliadas por eletroforese unidimensional em gel de poliacrilamida 10% SDS-PAGE e coradas com Coomasie Blue ou Nitrato de Prata. A concentração de proteínas totais não diferiu entre os grupos (p=0,1158) e foi de 6296,10 + 439,90μg/mL para o Grupo Controle e de 8426,56 + 1156,00μg/mL para o Grupo E2. Nos géis corados com Coomasie Blue foram identificadas 18 bandas protéicas e não foi observada diferença significativa (p>0,05) no perfil protéico dos explantes endometriais. Na coloração com Nitrato de Prata, foram identificadas 12 bandas protéicas... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: In cows the release of prostaglandin F2a (PGF2a) can be induced in vivo by estradiol (E2), however, the role of E2 in the synthesis of PGF2a has not yet been clarified. Considering that plasma concentrations of PGF2a increased 3.5 hours after application of E2 in vivo, it is believed that E2 not only active enzymes, but also stimulates the synthesis of essential proteins for the production of PGF2a, as PKC and PLA2 . This study aimed to evaluate the effect of E2 in increasing the concentration of total protein in the endometrium and changes in protein composition of endometrial explants from cows treated with E2 at the 17th day of estrous cycle. The hypothesis is that the administration of E2 in cows on the 17th day of the estrous cycle increases the concentration of protein in the endometrium and changes the composition of protein in endometrial explants. Therefore, days of the estrous cycle, crossbred cows were treated at 17th day of estrous cycle intravenously with 0 mg (Control Group; n = 6) or 3 mg of E2 (E2 Group; n = 6) and killed two hours after treatment. Endometrial explants were isolated and subjected to extraction of total protein. Samples of proteins related to the explants from each animal were analyzed by one-dimensional electrophoresis on polyacrylamide gel 10% SDSPAGE and stained with Coomasie Blue or silver nitrate. The concentration of total protein did not differ between groups (p = 0.1158) and was 6296.10 + 439.90μg/mL for the Control Group and of 8426.56 + 1156.00μg/mL for E2 Group. In gels stained with Coomasie Blue were identified 18 protein bands and there was no significant difference (p>0.05) in the protein profile of endometrial explants. Staining with Silver Nitrate, was identified 12 protein bands and was found in E2 Group greater relative percentage of the bands for the molecular weight of... (Complete abstract, click electronic access below) / Mestre

Made available in DSpace on 2014-06-11T19:27:18Z (GMT). No. of bitstreams: 0 Previous issue date: 2009-12-21Bitstream added on 2014-06-13T18:55:52Z : No. of bitstreams: 1 alvesjunior_ss_me_araca.pdf: 754821 bytes, checksum: 775497c7949e0db41b5df339f2c15776 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Fundação para o Desenvolvimento da UNESP (FUNDUNESP) / Em fêmeas bovinas, a liberação de prostaglandina F2a (PGF2a) pode ser induzida in vivo pelo estradiol (E2), entretanto, o papel do E2 na síntese de PGF2a ainda não foi esclarecido. Considerando que as concentrações plasmáticas de PGF2a aumentam 3,5 horas após a aplicação de E2 in vivo, acredita-se que o E2 ative não somente enzimas, mas também estimule a síntese de proteínas essenciais para a produção de PGF2a, como a PKC e PLA2. O presente estudo objetivou avaliar o efeito do E2 no incremento da concentração das proteínas totais no endométrio e na modificação da composição protéica de explantes endometriais de fêmeas bovinas tratadas com E2 no 17º dia do ciclo estral. A hipótese é que a administração de E2 em fêmeas bovinas no 17º dia do ciclo estral incrementa a concentração de proteínas no endométrio e modifica a composição protéica nos explantes endometriais. Para tanto, fêmeas bovinas mestiças (Bos taurus taurus vs Bos taurus indicus) foram tratadas no 17° dia do ciclo estral, via intravenosa, com 0mg (Grupo Controle; n=6) ou 3mg de E2 (Grupo E2; n=6) e abatidas duas horas após o tratamento. Explantes endometriais foram isolados e submetidos à extração de proteínas totais. As amostras de proteínas, referentes aos explantes de cada animal, foram avaliadas por eletroforese unidimensional em gel de poliacrilamida 10% SDS-PAGE e coradas com Coomasie Blue ou Nitrato de Prata. A concentração de proteínas totais não diferiu entre os grupos (p=0,1158) e foi de 6296,10 + 439,90μg/mL para o Grupo Controle e de 8426,56 + 1156,00μg/mL para o Grupo E2. Nos géis corados com Coomasie Blue foram identificadas 18 bandas protéicas e não foi observada diferença significativa (p>0,05) no perfil protéico dos explantes endometriais. Na coloração com Nitrato de Prata, foram identificadas 12 bandas protéicas... / In cows the release of prostaglandin F2a (PGF2a) can be induced in vivo by estradiol (E2), however, the role of E2 in the synthesis of PGF2a has not yet been clarified. Considering that plasma concentrations of PGF2a increased 3.5 hours after application of E2 in vivo, it is believed that E2 not only active enzymes, but also stimulates the synthesis of essential proteins for the production of PGF2a, as PKC and PLA2 . This study aimed to evaluate the effect of E2 in increasing the concentration of total protein in the endometrium and changes in protein composition of endometrial explants from cows treated with E2 at the 17th day of estrous cycle. The hypothesis is that the administration of E2 in cows on the 17th day of the estrous cycle increases the concentration of protein in the endometrium and changes the composition of protein in endometrial explants. Therefore, days of the estrous cycle, crossbred cows were treated at 17th day of estrous cycle intravenously with 0 mg (Control Group; n = 6) or 3 mg of E2 (E2 Group; n = 6) and killed two hours after treatment. Endometrial explants were isolated and subjected to extraction of total protein. Samples of proteins related to the explants from each animal were analyzed by one-dimensional electrophoresis on polyacrylamide gel 10% SDSPAGE and stained with Coomasie Blue or silver nitrate. The concentration of total protein did not differ between groups (p = 0.1158) and was 6296.10 + 439.90μg/mL for the Control Group and of 8426.56 + 1156.00μg/mL for E2 Group. In gels stained with Coomasie Blue were identified 18 protein bands and there was no significant difference (p>0.05) in the protein profile of endometrial explants. Staining with Silver Nitrate, was identified 12 protein bands and was found in E2 Group greater relative percentage of the bands for the molecular weight of... (Complete abstract, click electronic access below)

Thesis (M.S.)--University of Florida, 2004. / Typescript. Title from title page of source document. Document formatted into pages; contains 176 pages. Includes Vita. Includes bibliographical references.

Zhao Zheng. / "December 2000." / On t.p. "2" is subscript. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2000. / Includes bibliographical references (p. 187-241). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

Lau Yin Kei. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (leaves 58-79). / Abstracts in English and Chinese. / Acknowledgement --- p.I / Abstract --- p.IV / Abstract in Chinese --- p.VI / Abbreviations --- p.VIII / Introduction --- p.1 / Chapter 1.1 --- Prevalence of COPD and asthma in Hong Kong --- p.1 / Chapter 1.2 --- Players in pathogenesis of COPD --- p.2 / Chapter 1.3 --- Players in pathogenesis of asthma --- p.4 / Chapter 1.4 --- The use of exhaled breath condensate in previous studies --- p.6 / Chapter 1. 5 --- Brief overview of chemokines --- p.8 / Chapter 1.6 --- Objective of this study --- p.12 / Materials and methods --- p.14 / Chapter 2.1 --- Study population --- p.14 / Chapter 2.1.1 --- Patients with COPD and control subjects --- p.14 / Chapter 2.1.2 --- Patients with asthma and control subjects --- p.15 / Chapter 2.2 --- Lung function --- p.15 / Chapter 2.3 --- Dyspnoea score measurement of patients with COPD --- p.16 / Chapter 2.4 --- Classification of patients and asthma severity --- p.16 / Chapter 2.5 --- Skin prick test and blood tests --- p.16 / Chapter 2.6 --- Collection of exhaled breath condensate --- p.17 / Chapter 2.7 --- Measurement of constituent in EBC --- p.17 / Chapter 2.7.1 --- "Measurement of 8-isoprostane, MCP-1 and GROα in patients with COPD and the corresponding control subjects" --- p.17 / Chapter 2.7.2 --- Measurement of eotaxin and MDC of patients with asthma and the corresponding control subjects --- p.18 / Chapter 2.8 --- Reproducibility of exhaled breath constituent --- p.18 / Chapter 2.8.1 --- "Assessment of reproducibility of the exhaled MCP-1, GROα and8- isoprostane measurements" --- p.19 / Chapter 2.8.2 --- Assessment of reproducibility of the exhaled eotaxin and MDC measurement --- p.19 / Chapter 2.9 --- Statistical analysis --- p.19 / Results --- p.21 / Chapter 3.1 --- Patients with COPD and corresponding control subjects --- p.21 / Chapter 3.2 --- Patients with asthma and corresponding control subjects --- p.28 / Discussion --- p.36 / Chapter 4.1 --- "Exhaled 8-isoprostane, GRO-α and MCP-1 of patients with COPD and corresponding control subjects" --- p.36 / Chapter 4.2 --- Exhaled eotaxin and MDC from patients with asthma and corresponding control subjects --- p.43 / Chapter 4.3 --- Technical aspects of EBC assessment --- p.49 / Future prospect --- p.54 / Conclusion --- p.56 / References --- p.58 / Tables and Figures / Table 1. Demographics of the COPD and control subjects --- p.22 / Figure 1. The level of 8-isoprostane in the exhaled breath condensate of COPD and control subjects --- p.23 / Figure 2. The level of GROa in the exhaled breath condensate of COPD and control subjects --- p.25 / "Figure 3 Bland and Altman's Plot of the repeatability of 8-isoprostane, GROa and MCP-1 in the exhaled breath condensate of normal controls" --- p.27 / Table2. Clinical and physiological details of the subjects --- p.29 / Figure 4. Level of eotaxin in exhaled breath condensate of asthma and control subjects --- p.30 / Figure 5 Level of MDC in exhaled breath condensate of asthma and control subjects --- p.31 / Table 3. Levels of eotaxin and MDC in exhaled breath condensate of asthma subjects on different dose of inhaled corticosteroids --- p.33 / Figure 6. Relationship between exhaled breath condensate level of MDC and total serum IgE level --- p.35